{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Mediated+Amyloidosis+%28ATTR%29",
    "query": {
      "condition": "Transthyretin Mediated Amyloidosis (ATTR)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Mediated+Amyloidosis+%28ATTR%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:21:22.444Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07358078",
      "title": "DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Amyloidosis With Cardiomyopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2026-01-09",
      "completion_date": "2030-10-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 4,
      "location_summary": "Naples, Florida • Boston, Massachusetts • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07358078"
    },
    {
      "nct_id": "NCT01981837",
      "title": "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "ALN-TTRSC (revusiran) for subcutaneous administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2013-12",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981837"
    },
    {
      "nct_id": "NCT01617967",
      "title": "Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 29,
      "start_date": "2012-05",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617967"
    },
    {
      "nct_id": "NCT04418024",
      "title": "Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "AG10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-10-21",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418024"
    },
    {
      "nct_id": "NCT04569903",
      "title": "Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Computer algorithm for ATTR",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-08-01",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569903"
    },
    {
      "nct_id": "NCT04136184",
      "title": "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Inotersen",
          "type": "DRUG"
        },
        {
          "name": "Eplontersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 168,
      "start_date": "2019-12-11",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04136184"
    },
    {
      "nct_id": "NCT04306510",
      "title": "A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hereditary Transthyretin Amyloidosis With Polyneuropthy"
      ],
      "interventions": [
        {
          "name": "TEGSEDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akcea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-01-21",
      "completion_date": "2024-03-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-10",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 1,
      "location_summary": "Rosedale, New York",
      "locations": [
        {
          "city": "Rosedale",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306510"
    },
    {
      "nct_id": "NCT01961921",
      "title": "The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "ALN-TTR02 (patisiran) administered by intravenous (IV) infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2013-10",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01961921"
    },
    {
      "nct_id": "NCT02510261",
      "title": "The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 211,
      "start_date": "2015-07-16",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 14,
      "location_summary": "La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510261"
    },
    {
      "nct_id": "NCT06128629",
      "title": "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "NTLA-2001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Intellia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 1200,
      "start_date": "2023-12-13",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-05-22T09:21:22.444Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06128629"
    }
  ]
}